Manhattan BioSolutions, Inc. Announces Collaborative Poster Presentation on Novel FGFR4-Targeted ADC at AACR Annual Meeting 2024

NEW YORK - April 9, 2024 - PRLog -- Manhattan BioSolutions, Inc. ("Manhattan Bio"), an emerging biotechnology company developing new classes of precision biologics for the treatment of advanced cancers, today announced a collaborative poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. The poster, titled "A potent FGFR4-targeted antibody-drug conjugate therapy for patients with rhabdomyosarcoma and other cancers expressing FGFR4," highlights the promising preclinical efficacy of this innovative therapeutic approach. The research is a result of a collaboration between Manhattan Bio, the National Cancer Institute (NCI), part of the US National Institutes of Health (NIH), and Binghamton University.

The lead investigator is Javed Khan, MD, Senior Investigator and Deputy Chief of the Genetics Branch at the NCI Center for Cancer Research. The study utilized a highly specific monoclonal antibody that targets FGFR4, a receptor overexpressed in various cancers, including rhabdomyosarcoma (RMS). The antibody was conjugated to the cytotoxic MMAE payload through a protease-cleavable valine-citrulline linker, generating a potent FGFR4-targeted ADC. This work builds on an earlier collaboration agreement between Manhattan Bio, the NCI, and Binghamton University announced in 2023.

"We are thrilled to share the compelling preclinical data generated through our ongoing collaboration with the NCI and Binghamton University," said Dr. Borys Shor, CEO of Manhattan Bio. "While this proof-of-concept study utilized a standard linker-payload system, we are excited to continue our work with cutting-edge topoisomerase 1 inhibitor warheads currently being developed at Manhattan Bio. We believe that by combining the highly selective FGFR4 antibody with our proprietary linker-payload technologies, we can further enhance the therapeutic potential of this ADC for pediatric patients with RMS and for patients with other types of tumors."

About Manhattan BioSolutions
Manhattan BioSolutions, Inc is a privately held biotechnology company focused on the development of biologic therapies targeting host defense pathways for the treatment of advanced cancers. The company advances two technology platforms for drug discovery: RNA-degrader proteins, and antibody-drug conjugates (ADCs) - through collaborations with leading academic institutions. Manhattan Bio has established partnerships with the National Cancer Institute (NCI), Stony Brook University, The University at Buffalo, Binghamton University, INSERM, Nascent Biotech, EVQLV, and has been awarded grants by the National Institutes of Health (NIH), the National Science Foundation (NSF), the New Jersey Commission on Science, Innovation and Technology (CSIT), the New York State Center For Biotechnology and the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UBCAT). Learn more at and follow Manhattan BioSolutions on LinkedIn or X-Twitter (

Contact for investor inquiries:
Borys Shor, Ph.D

Like PRLog?
Click to Share